IDSC Fellows
On Tuesday, April 30, 2024, from 3:00-5:00 PM, an audience gathered via Zoom and in person at the Richter Library 3rd floor conference room to hear the 2023-2024 IDSC Fellows give their final research project presentations. If you missed it, catch the replay on YouTube: Read more “Catch the Replay: 2023-2024 IDSC Fellows Final Research Project Presentations”
Events
The four outstanding students selected as the 2023-2024 IDSC Fellows gave their initial project presentations at a launch symposium held at the Richter Library on November 28. This was followed by presentations from the inaugural cohort of the Provost’s Fellowship in Interdisciplinary Computing awardees. If you missed it, watch on our YouTube Channel. Read more “IDSC Fellows Final Research Project Presentations 4/30”
The four outstanding students selected as the 2023-2024 IDSC Fellows presented their proposed projects at a launch symposium held at the Richter Library on November 28. This was followed by presentations from the inaugural cohort of the Provost’s Fellowship in Interdisciplinary Computing awardees. Read more “2023-2024 IDSC Fellows Capstone Event 4/30”
Publications
Glioblastoma (GBM) is the most common and malignant adult brain tumor. Despite years of research, few advancements have been made in its management. One promising avenue of research has been treatment with BRD4 inhibitors, which decrease oncogene expression in GBM cells. Read more “Gene 36. Integrating Transcriptomics and Kinomics Identifies Synergistic Drug Combinations for Glioblastoma Treatment”
News
Glioblastoma (GBM) remains the most common adult brain tumor, with poor survival expectations, and no new therapeutic modalities approved in the last decade. Our laboratories have recently demonstrated that the integration of a transcriptional disease signature obtained from Read more “Comp-16. Comprehensive Transcriptomic Analysis of Single Cells From Recurrent and Primary Glioblastoma to Predict Cell-Type-Specific Therapeutics”
Publications
Glioblastoma multiforme (GBM) is the most malignant primary adult brain tumor. The current standard of care is surgical resection, radiation, and chemotherapy treatment, which extends life in most cases. Unfortunately, tumor recurrence is nearly universal and patients with recurrent glioblastoma typically survive less than one year. Read more “Drug Repositioning in Glioblastoma: A Pathway Perspective”